Ligand-binding sites in human serum amyloid P component

被引:18
|
作者
Heegaard, NHH
Heegaard, PMH
Roepstorff, P
Robey, FA
机构
[1] DANISH VET LAB, DEPT BIOCHEM & IMMUNOL, COPENHAGEN, DENMARK
[2] ODENSE UNIV, DEPT MOL BIOL, DK-5230 ODENSE, DENMARK
[3] NIDR, NIH, PEPTIDE & IMMUNOCHEM UNIT, BETHESDA, MD 20892 USA
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 1996年 / 239卷 / 03期
关键词
amyloid P component; heparin; Alzheimers capillary electrophoresis; peptide;
D O I
10.1111/j.1432-1033.1996.0850u.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Amyloid P component (AP) is a naturally occurring glycoprotein that is found in serum and basement membranes, AP is also a component of all types of amyloid, including that found in individuals who suffer from Alzheimer's disease and Down's syndrome. Because AP has been found to bind strongly and specifically to certain glycosaminoglycans that are components of amyloid deposits, AP may play an important role in the maintenance of amyloid. In the present work, we isolated and identified two proteolytic fragments of AP that are responsible for its heparin-binding activity. Neither fragment corresponds to published heparin-binding sequences. The structural requirements for activity of the peptides (amino acid residues 27-38 and 192-203 of AP) were examined by means of solid-phase inhibition assays with synthetic peptides, AP-(192-203)-peptide inhibits the Ca2+-dependent binding of AP to heparin with an IC50 of 25 mu M, while the IC50 of AP-(27-38)-peptide and AP-(33-38)-peptide are 10 mu M and 2 mu M, respectively, The understanding of the structure and function of active AP peptides will be useful for development of amyloid-targeted diagnostics and therapeutics.
引用
收藏
页码:850 / 856
页数:7
相关论文
共 50 条
  • [21] CHARACTERIZATION OF LIGAND-BINDING SITES OF THE HUMAN A1 ADENOSINE RECEPTOR
    RIVKEES, SA
    LASBURY, M
    BARBHAIYA, H
    PEDIATRIC RESEARCH, 1995, 37 (04) : A97 - A97
  • [22] BINDING OF SERUM AMYLOID P COMPONENT TO ZYMOSAN INVOLVES A (PHOSPHO)-MANNOSE OLIGOSACCHARIDE-CONTAINING LIGAND
    GEWURZ, AT
    KUBAK, BM
    POTEMPA, LA
    ANDERSON, B
    GEWURZ, H
    CLINICAL RESEARCH, 1987, 35 (06): : A895 - A895
  • [23] Automated prediction of ligand-binding sites in proteins
    Harris, Rodney
    Olson, Arthur J.
    Goodsell, David S.
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2008, 70 (04) : 1506 - 1517
  • [24] CHARACTERISTICS OF THE BINDING OF SERUM AMYLOID-P COMPONENT TO CHROMATIN
    GEWURZ, A
    KINOSHITA, CM
    YING, SC
    GUPTA, R
    EATMAN, J
    GEWURZ, H
    FASEB JOURNAL, 1988, 2 (05): : A1180 - A1180
  • [25] Immunoradiometric assay for human serum amyloid P component
    Millar, David J.
    Hutchinson, Winston L.
    Pepys, Mark B.
    JOURNAL OF IMMUNOLOGICAL METHODS, 2011, 371 (1-2) : 18 - 24
  • [26] Isoforms of murine and human serum amyloid P component
    Nybo, M
    Hackler, R
    Kold, B
    Nielsen, EH
    Steinmetz, A
    Svehag, SE
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1998, 48 (04) : 350 - 356
  • [27] SERUM AMYLOID P-COMPONENT - BINDING TO AMYLOID FIBRILS AND IMMUNOHISTOCHEMICAL STAINING IN NORMAL HUMAN-TISSUES
    PEPYS, MB
    DYCK, RF
    DEBEER, FC
    KERSHAW, M
    CLINICAL SCIENCE, 1980, 58 (02) : P17 - P18
  • [28] Practical aspects of the ligand-binding and enzymatic properties of human serum albumin
    Kragh-Hansen, U
    Chuang, VTG
    Otagiri, M
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2002, 25 (06) : 695 - 704
  • [29] THE EFFECT OF NONENZYMATIC GLYCATION ON LIGAND-BINDING TO HUMAN-SERUM ALBUMIN
    FITZPATRICK, G
    DUGGAN, PF
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1987, 15 (02) : 267 - 268
  • [30] Serum amyloid P component (not Serum Amyloid Protein)
    M.B. Pepys
    Nature Medicine, 1999, 5 : 852 - 853